Tubulin-polymerization inhibitors derived from thalidomide

被引：30
作者：
Inatsuki, S
Noguchi, T
Miyachi, H
Oda, S
Iguchi, T
Kizaki, M
Hashimoto, Y
Kobayashi, H
机构：
[1] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan
[2] Keio Univ, Sch Med, Div Hematol, Shinjuku Ku, Tokyo 1608582, Japan
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2005年 / 15卷 / 02期
基金：
日本学术振兴会;
关键词：
thalidomide; tubulin; polymerization; inhibitor;
D O I：
10.1016/j.bmcl.2004.10.072
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
2-(2,6-Diisopropylphenyl)-5-hydroxy-1H-isoindole-1,3-dione (5HPP-33), which was obtained during our previous structural development studies on thalidomide, was revealed to possess potent tubulin-polymerization-inhibiting activity, comparable to that of the known tubulin-polymerization inhibitors, rhizoxin and colchicine. A major metabolite of thalidomide, 5-hydroxythalidomide, which possesses a hydroxyl group at the position corresponding to that of 5HPP-33, also showed moderate inhibitory activity. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码：321 / 325
页数：5
相关论文
共 33 条
[1]   Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents [J].
Bartlett, JB ;
Dredge, K ;
Dalgleish, AG .
NATURE REVIEWS CANCER, 2004, 4 (04) :314-322
[2]   Thalidomide: Current and potential clinical applications [J].
Calabrese, L ;
Fleischer, AB .
AMERICAN JOURNAL OF MEDICINE, 2000, 108 (06) :487-495
[3]   An expeditious synthesis of cyclic imides [J].
Flaih, N ;
Pham-Huy, C ;
Galons, H .
TETRAHEDRON LETTERS, 1999, 40 (19) :3697-3698
[4]   Thalidomide on the comeback trail [J].
Hales, BF .
NATURE MEDICINE, 1999, 5 (05) :489-490
[5]   Structural development of biological response modifiers based on thalidomide [J].
Hashimoto, Y .
BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (03) :461-479
[6]  
Hashimoto Y, 1998, CURR MED CHEM, V5, P163
[7]   Structural Development of Biological Response Modifiers Based on Retinoids and Thalidomide [J].
Hashimoto, Yuichi .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2002, 2 (06) :543-551
[8]   Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy [J].
Hideshima, T ;
Chauhan, D ;
Shima, Y ;
Raje, N ;
Davies, FE ;
Tai, YT ;
Treon, SP ;
Lin, B ;
Schlossman, RL ;
Richardson, P ;
Muller, G ;
Stirling, DI ;
Anderson, KC .
BLOOD, 2000, 96 (09) :2943-2950
[9]  
Hu ZG, 2003, ABSTR PAP AM CHEM S, V225, pU196
[10]   Anti-androgens with full antagonistic activity toward human prostate tumor LNCaP cells with mutated androgen receptor [J].
Ishioka, T ;
Tanatani, A ;
Nagasawa, K ;
Hashimoto, Y .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (16) :2655-2658
1234